Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report describes the dermoscopic features of two cases of the tumor of the follicular infundibulum, contributing new insights as they had not been previously detailed in the literature.

This review discusses the dual role of the Wnt/β-catenin pathway in mammalian tissue injury, highlighting its potential for both promoting regeneration and contributing to fibrosis, but presents no new findings.

The researchers reported that topical application of small-molecule Wnt inhibitors significantly reduced fibrosis and promoted regenerative wound healing in mice.

This study observed that baricitinib led to significant hair regrowth and improved psychological well-being in severe alopecia areata patients over 48 weeks, with 63.2% achieving a SALT score of ≤20.

Accurate diagnosis is crucial to distinguish alopecia areata incognita from androgenetic alopecia in men for proper treatment.

This pilot study found that using skin patting and iontophoresis to deliver a 6% dutasteride gel led to significant improvements in hair density and shaft diameter in men and postmenopausal women with treatment-resistant androgenetic alopecia, with no reported adverse events.

Chemicals and stem cells combined have advanced regenerative medicine with few safety concerns, focusing on improving techniques and treatment effectiveness.

This systematic review provides a detailed overview of the clinical and dermoscopic features of cutaneous adnexal tumors, highlighting their potential to mimic other skin lesions and assisting in differential diagnosis.

This study found that dupilumab's effects on alopecia areata varied depending on patients' immune profiles, with Th2-skewed females seeing improvements and Th1-driven males experiencing worsening.

The EADV Task Force on Hair Diseases reviewed existing literature and clinical experience to propose diagnostic and therapeutic recommendations for managing folliculitis decalvans, highlighting oral antibiotics, glucocorticosteroids, isotretinoin, and various systemic and topical therapies as key options for managing inflammation and preventing further hair loss.

In this Italian retrospective study, ritlecitinib 50 mg/day showed effectiveness and good tolerability for treating severe alopecia areata over 24 weeks, achieving significant hair regrowth particularly in adolescents, as well as improvements in eyebrows, eyelashes, nails, and quality of life, with mostly mild adverse effects.

This review suggests that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have potential benefits for dermatologic conditions but may also cause adverse skin reactions and impact surgical outcomes.

This study found that the STRIAA scoring tool provides a rapid and highly reliable assessment of alopecia areata severity, showing a significant correlation with the traditional SALT score, thus enhancing clinical evaluation in patients with this condition.

This review article examines the current understanding of frontal fibrosing alopecia, noting its prevalence in different demographics and the roles of genetic and environmental factors in its pathogenesis, while highlighting that treatment approaches remain varied and lack standardization.

This study supports the use of a national registry as an effective tool for documenting epidemiological data, disease progression, treatment responses, and quality of life impacts in patients with alopecia areata.

In this review, researchers outline the characteristics of scalp rosacea, an underrecognized inflammatory dermatosis, describing its multifactorial pathogenesis, diagnostic features, and management strategies, noting its clinical similarities with facial rosacea and the absence of standardized diagnostic criteria or therapeutic guidelines.

This abstract does not report results but indicates that the supplementary material includes comprehensive methodology, additional results, statistical analyses, discussion, and limitations of the Alopecia Areata Relapse Study Group's findings as presented in the main manuscript.

This review assessed trichoscopic findings in folliculotropic mycosis fungoides of the scalp, reporting features like milky-red globules and distinct vascular patterns, but noted the predominance of small studies and the need for larger research to validate trichoscopy's diagnostic utility for this condition.

In this scoping review, researchers observed that while AI-assisted trichoscopy holds promise for standardized assessments of hair and scalp disorders, its clinical translation is limited by small proprietary datasets, inconsistent validation protocols, and a scarcity of real-world clinical studies.

In this study, topical finasteride 0.25% showed sustained effectiveness over 52 weeks, especially in the frontotemporal areas of men with androgenetic alopecia, while maintaining an excellent safety profile.

In this study, patients with severe alopecia areata who were treated with baricitinib 4 mg/day for 48 weeks showed significant improvements in both hair regrowth and nail abnormalities, although the correlation between hair and nail improvement was weak.

This real-world study found that baricitinib 4 mg daily was effective in promoting hair regrowth and improving psychological well-being in Italian adults with severe alopecia areata over 48 weeks, with 63.2% of patients achieving significant hair recovery and 9.4% experiencing adverse events.

This pilot study found that using skin patting with iontophoresis to deliver dutasteride gel significantly improved hair density, shaft diameter, and pull test scores in men and postmenopausal women with treatment-resistant androgenetic alopecia, with participants reporting high satisfaction and no adverse events.

In this study, researchers characterized alopecia areata incognita in men, finding that all 29 male patients had concurrent androgenetic alopecia, and treatment with ultra-potent topical corticosteroids and minoxidil led to remission in 4-8 months.

This systematic review and meta-analysis found that mood stabilizers used for bipolar disorder, such as lithium, valproate, carbamazepine, and lamotrigine, resulted in varying prevalence of dermatologic side effects, with lamotrigine showing the highest rash incidence, while severe reactions were rare.

This study found that epidermal growth factor receptor inhibitors can induce erosive pustular dermatosis of the scalp, typically appearing sooner and affecting the scalp more extensively compared to other triggers.

This study highlights the complexity of diagnosing scalp fungal infections, emphasizing how clinical evaluation, trichoscopy, and cultural samples are essential in distinguishing tinea capitis from similar conditions like piedra, seborrheic dermatitis, and psoriasis, due to overlapping symptoms like scaling and hair changes.

This study found that baricitinib significantly reduced hair loss in patients with severe alopecia areata, decreasing the mean SALT score from 96.6 to 48 over 24 weeks, with no patients dropping out and only mild adverse events in 12.7% of participants.

In this study, researchers developed and tested an Italian version of the Skindex-16AA to assess Health-Related Quality of Life in patients with moderate-to-severe Alopecia Areata, emphasizing the importance of patient perception in evaluating their mental health and quality of life.